The firm previously acted for the company in a pioneering merger
Thomson Geer has continued its work with an Australian life sciences company, which has struck a deal with a leading animal health firm for its canine anti-cancer drug.
Thomson Geer acted for QBiotics Group on its agreement with French-headquartered Virbac for the marketing and distribution of tigilanol tiglate to the US, Swiss, Norwegian, UK, and European markets.
Financial details of the transaction were not disclosed. The deal has the possibility to expand to Australia, New Zealand, and Canada, Thomson Geer said.
As many as one in four dogs will develop cancer, while almost half of all dogs over 10 years will die of cancer. There few drugs available to treat cancer in animals. Tigilanol Tiglate has demonstrated its potential to fight cancer in a range of solid tumours in dogs during clinical trials.
QBiotics is banking on the launch of the drug in veterinary markets to provide cash flow to further develop the drug for application to human cancers and wound healing.
The deal continues the work of Thomson Geer with QBiotics. Last year, it assisted the company in a pioneering merger transaction.
